CNTX — Context Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Brief: Bioatla And Context Therapeutics Announce Exclusive Worldwide License Agreement To Develop And Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Brief: Context Therapeutics Appoints Karen Smith, Luke Walker To Board
Brief: Context Therapeutics Board Increased Its Size From Five Members To Seven Members
Brief: Context Therapeutics Appoints Chief Medical Officer And Vice President Of Clinical Operations
Context Therapeutics rises after acquiring experimental cancer therapy for $3.75 mln
Brief: Context Therapeutics Acquires Phase 1-Ready T Cell Engager CT-95
Brief: Nextech Crossover I SCSP Reports 9.9% Passive Stake In Context Therapeutics
Brief: Context Therapeutics Files For Shelf Of Up To 64.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Deep Track Capital Reports Passive Stake Of 9.89% In Context Therapeutics As Of May 2, 2024
Brief: Context Therapeutics Expects To Enroll First Patient Mid-2024
Brief: Context Therapeutics Submits IND Application To Evaluate CTIM-76 In Claudin 6-Positive Cancers
Brief: Context Therapeutics Says Co Amended Collaboration, Licensing Agreement With Integral Molecular
Brief: Context Therapeutics Announces Preclinical Data Demonstrating
Brief: Context Therapeutics Inc. Q2 basic EPS USD -0.31
Brief: Context Therapeutics Received Letter From Nasdaq On June 15, Notifying That Co Has Regained Compliance With Minimum Bid Price Rule
Brief: Context Therapeutics Reports First Quarter 2023 Operating And Financial Results
U.S. STOCKS ON THE MOVE-Manchester United, Verona Pharma, 89Bio
U.S. STOCKS ON THE MOVE-Ollie, Commercial Metals, Copper Aluminum miners
U.S. STOCKS ON THE MOVE-U.S. banks, Regeneron, Gold miners